Disease · MONDO_0043653

herpes labialis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. herpes labialis. Diseases, record MONDO_0043653. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043653

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: herpes labialis; Open Targets
Open Targets ID: MONDO_0043653; Open Targets
Other names: cold sore, cold sores; Open Targets
MeSH: D006560; MeSH
NCI Thesaurus: C34695; NCI Thesaurus
Highest stage of its drugs: Approval, for 11 of its 23 drugs, from DailyMed; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ACYCLOVIR	CHEMBL184	Small molecule	Approval	DailyMed	15	8	8	Drugs and targets
FAMCICLOVIR	CHEMBL880	Small molecule	Approval	DailyMed	18	2	2	Drugs and targets
PENCICLOVIR	CHEMBL1540	Small molecule	Approval	DailyMed	5	2	2	Drugs and targets
HYDROCORTISONE	CHEMBL389621	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
VALACYCLOVIR	CHEMBL1349	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
VALACYCLOVIR HYDROCHLORIDE	CHEMBL1201110	Small molecule	Approval	DailyMed	6	0	0	Drugs and targets
CAMPHOR	CHEMBL15768	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
MENTHOL	CHEMBL256087	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
PHENOL	CHEMBL14060	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
AVOBENZONE	CHEMBL1200522	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
TRPA1	Transient receptor potential cation channel subfamily A member 1	1	Transient receptor potential cation channel subfamily A member 1 opener	Approval	https://conductscience.org/library/genes/8989	Drugs and targets
TRPM8	Transient receptor potential cation channel subfamily M member 8	1	Transient receptor potential cation channel subfamily M member 8 opener	Approval	https://conductscience.org/library/genes/79054	Drugs and targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02265913	Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis	Phase 3	4,076	2021-01-05	Herpes Labialis	ACYCLOVIR	Its record names the disease	ClinicalTrials.gov
NCT05098938	A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally	Phase 3	2,020	2025-09-02	Recurrent Herpes Labialis	ACYCLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00769314	Phase 3 Clinical Study for the Treatment of Cold Sore	Phase 3	1,727	2012-12-21	Herpes Labialis	ACYCLOVIR	Its record names the disease	ClinicalTrials.gov
NCT01985321	Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores	Phase 2	469	2015-05-28	Recurrent Herpes Labialis	ALCOHOL, GLYCOLIC ACID	Its record names the disease	ClinicalTrials.gov
NCT03192306	Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores	Phase 2	451	2018-08-16	Recurrent Herpes Labialis	ALCOHOL, ISOXAFLUTOLE	Its record names the disease	ClinicalTrials.gov
NCT02871492	Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes	Phase 2	362	2021-07-13	Herpes Labialis	ACYCLOVIR, PRITELIVIR	Its record names the disease	ClinicalTrials.gov
NCT01574612	Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old	Phase 3	54	2014-05-22	Herpes Labialis	ACYCLOVIR, HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT01971385	Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis	Phase 1	54	2017-10-02	Herpes Labialis	SQUARIC ACID DIBUTYL ESTER	Its record names the disease	ClinicalTrials.gov
NCT00878072	Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis	Phase 2/3	53	2021-06-25	Herpes Labialis	FAMCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT03661541	Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)	Phase 1	36	2021-11-03	HSV, Herpes Labialis	SQUARIC ACID DIBUTYL ESTER	Its record names the disease	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sitavig vs Placebo: deaths from any cause	1 of 504	0 of 497	1,001	NCT05098938	Trial comparisons
Sitavig vs Placebo: serious adverse events	5 of 504	7 of 497	1,001	NCT05098938	Trial comparisons
Acyclovir Lauriad Group vs Placebo Group: serious adverse events	0 of 378	1 of 397	775	NCT00769314	Trial comparisons
Merlin - Ethanol/Glycolic Acid Solution vs Ethanol: serious adverse events	0 of 90	0 of 83	173	NCT01985321	Trial comparisons
Merlin - Ethanol/Glycolic Acid Solution vs Ethanol: Number of Treatment Related Adverse Events	9 of 89	3 of 83	172	NCT01985321	Trial comparisons
Merlin vs Ethanol: deaths from any cause	0 of 76	0 of 80	156	NCT03192306	Trial comparisons
Merlin vs Ethanol: serious adverse events	0 of 76	0 of 80	156	NCT03192306	Trial comparisons
Merlin vs Ethanol: Clinician Assessed Prevention of Progression to Classical Lesion	12 of 75	6 of 80	155	NCT03192306	Trial comparisons
Study Drug (EDTA Eye Drops) vs Active Comparator (Abreva): deaths from any cause	0 of 5	0 of 5	10	NCT04893577	Trial comparisons
Study Drug (EDTA Eye Drops) vs Active Comparator (Abreva): serious adverse events	0 of 5	0 of 5	10	NCT04893577	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30756512	RESULT	1	PubMed
21178655	DERIVED	1	PubMed
19143902	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0043653

GET https://conductscience.org/api/diseases/v1/MONDO_0043653/drugs?page=2

API reference For AI assistants